Old Web
English
Sign In
Acemap
>
authorDetail
>
Alison K. Cardenas
Alison K. Cardenas
Genentech
Internal medicine
Adverse effect
Clinical trial
Onartuzumab
Bevacizumab
2
Papers
51
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Phase II Study of Taselisib (GDC‑0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer
2018
Clinical Cancer Research
Maura N. Dickler
Cristina Saura
Donald A. Richards
Ian E. Krop
Andrés Cervantes
Philippe L. Bedard
Manish R. Patel
Lajos Pusztai
Mafalda Oliveira
Alison K. Cardenas
Na Cui
Timothy R. Wilson
Tj Stout
Michael C. Wei
Jerry Y. Hsu
José Baselga
Show All
Source
Cite
Save
Citations (36)
Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program
2015
PLOS ONE
Roland Morley
Alison K. Cardenas
Peter Hawkins
Yasuyo Suzuki
Virginia E. Paton
See-Chun Phan
Mark Merchant
Jessie J. Hsu
Wei Yu
Qi Xia
Daniel O. Koralek
Patricia Luhn
Wassim Aldairy
Show All
Source
Cite
Save
Citations (15)
1